Giuliana Grossi

Why is Rare Disease Day so important? Hear the answers from some of the most qualified professionals in rare disease fields.

Vibeke Strand, MD, shares that based on her data, secukinumab is an effective option for treating patients with psoriatic arthritis.

The Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force shares what was learned from the Omicron variant and how the recommendations for rheumatologists has been affected by it.

Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force, Jeffrey Curtis, discusses the newest vaccine recommendations amid the Omicron variant.

Vibeke Strand explains that secukinumab improves psoriatic arthritis in patients regardless of their treatment history.

Phase 3 of the FUTURE 5 trial further examined the efficacious effect that secukinumab had on patients with psoriatic arthritis.

The fifth update from the American College of Rheumatology supports fourth doses of the vaccine for high-risk rheumatic disease patients.

The FDA was prompted to require a safety trial comparing tofacitinib with TNF inhibitors in patients with rheumatoid arthritis.

New data show that even though physical therapy may be the more expensive treatment for knee osteoarthritis, it’s more effective than intra-articular glucocorticoid injection.

Contrary to recent research that indicated a higher risk of death associated with escalating doses of allopurinol for chronic kidney disease, investigators announce no association between allopurinol initiation and increased mortality among patients with gout and CKD.

Promising results were announced by UCB after a Phase 3 study evaluated bimekizumab for non-radiographic axial spondyloarthritis and met all endpoints.

Investigators closely examine the differences between neuromuscular changes associated with normal aging and those associated with age-related disorders and how they affect individuals with knee osteoarthritis.

Novartis receives approval for Cosentyx, their biologic treatment for enthesitis-related arthritis and juvenile psoriatic arthritis, in children and adolescents.

Guselkumab is the first and only selective interleukin inhibitor therapy in the US that's approved for both moderate-severe plaque psoriasis and active psoriatic arthritis regardless of prior TNFi exposure.

A correlation between disease activity and overall hand functionality was discovered in patients with psoriatic arthritis.

Continual improvement was shown in patient-reported pain levels when treated with guselkumab compared with placebo.

Results show that antimetabolites and BCDT medications were frequently represented in the group of vaccinated patients who were hospitalized for COVID-19.

Interventions for patients with systemic lupus erythematosus (SLE) need to address physician/patient communication to improve health outcomes, according to Dr. Maheswaranathan.

Patients who are treated with B cell depletion therapies show that their B cell count at time of vaccination can impact their COVID-19 antibody response.

Late-breaking data from ACR 2021 shows that most of the fully vaccinated patients with breakthrough infections of SARS-COV-2 were on anti-metabolites or BCDT.

Lower health literacy has been found to be associated with worsened health outcomes for patients with systemic lupus erythematosus (SLE).

A study presented at ACR 2021 found that CBD had no significant effect on pain intensity in patients with hand osteoarthritis or psoriatic arthritis.

This study shows that many patients with rheumatoid arthritis can use a dose lower than 1000mg and still see results.

With the popularity of CBD growing in Denmark, Jonathan Vela, MD, examined the effectiveness of CBD treatment on hand osteoarthritis and psoriatic arthritis.

In this video interview, Dr. Jing Cui explains what the next steps could be for the risk prediction models of systemic lupus erythematosus.

In this video interview, Dr. Edigin talks about the importance of outpatient care in reducing hospitalizations for SLE flare.

Nathan den Broeder, MSs, shares the findings of his study at the ACR 2021 Convergence.

Research presented by Dr. Jing Cui at ACR 2021 Convergence identified significant risk factors for systemic lupus erythematosus in a risk prediction model study.

Research results shows that while overall hospitalization for SLE flare decreased, it increased among African American patients.

Dr. Jing Cui speaks about how she examined lifestyle and environmental factors as well as genetic risk to assess risk of systemic lupus erythematosus.